St. Jude Neuromodulation draws warning letter
This article was originally published in The Gray Sheet
FDA warning letter dated July 1 cites non-conformities with current good manufacturing practices at St. Jude's Neuromodulation division facilities in Plano, Tex., and Hackettstown, N.J., which were observed during FDA inspections in March and April. St. Jude says it has already begun addressing the issues, which pertain to manufacturing process and documentation issues, and not specific device deficiencies, according to the company. FDA says it will not approve any St. Jude Neuromodulation PMA application until the warning letter is resolved. But St. Jude notes that it does not have any major neuromodulation device filings pending. The company recently completed enrollment of a pivotal study of its Libra and LibraXP deep brain stimulation systems for symptomatic Parkinson's disease. The company says it expects to file a PMA for the indication in about 18 months
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.